Results 21 to 30 of about 64,866 (299)

Cancer cachexia

Journal of Parenteral and Enteral Nutrition, 1988
Cancer cachexia describes a syndrome of progressive weight loss, anorexia, and persistent erosion of host body cell mass in response to a malignant growth. Although often associated with preterminal patients bearing disseminated disease, cachexia may be present in the early stages of tumor growth before any signs or symptoms of malignancy. A decline in
K A, Kern, J A, Norton
openaire   +5 more sources

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors

Thoracic Cancer, 2023
Background The presence of cachexia in cancer patients negatively affects the quality of life and survival. However, the impact of cachexia on immunotherapy, such as PD‐1/L1 inhibitors, is not fully understood.
Norikazu Matsuo, Koichi Azuma, Kenta Murotani, Daiki Murata, Goushi Matama, Akihiko Kawahara, Takashi Kojima, Takaaki Tokito, Tomoaki Hoshino   +8 more
doaj   +1 more source

Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series. [PDF]

The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy.
Coats, AJS, Hjermstad, MJ, Bye, A, Grzyb, A, Arends, J, Ottestad, I, Sayers, J, Sousa, MS, Simpson, MR, Skipworth, RJE, Balstad, TR, Koteng, LH, Greil, C, McDonald, J, Cancer Cachexia Endpoints Working Group,, Dajani, OF, Brown, LR, Vagnildhaug, OM, Laird, BJA, May, AM, Solheim, TS, Philips, I, Dolan, RD, Jakobsen, G, Roeland, EJ, Fallon, MT, Kaasa, S   +26 more
core   +3 more sources

Circulating monocyte chemoattractant protein‐1 (MCP‐1) is associated with cachexia in treatment‐naïve pancreatic cancer patients

Journal of Cachexia, Sarcopenia and Muscle, 2018
Background Cancer‐associated wasting, termed cancer cachexia, has a profound effect on the morbidity and mortality of cancer patients but remains difficult to recognize and diagnose.
Erin E. Talbert, Heather L. Lewis, Matthew R. Farren, Mitchell L. Ramsey, Jeffery M. Chakedis, Priyani Rajasekera, Ericka Haverick, Angela Sarna, Mark Bloomston, Timothy M. Pawlik, Teresa A. Zimmers, Gregory B. Lesinski, Phil A. Hart, Mary E. Dillhoff, Carl R. Schmidt, Denis C. Guttridge   +15 more
doaj   +1 more source

Cardiac Remodeling in Cancer-Induced Cachexia: Functional, Structural, and Metabolic Contributors

Cells, 2022
Cancer cachexia is a syndrome of progressive weight loss and muscle wasting occurring in many advanced cancer patients. Cachexia significantly impairs quality of life and increases mortality. Cardiac atrophy and dysfunction have been observed in patients
Michael P. Wiggs, Anna G. Beaudry, Michelle L. Law   +2 more
doaj   +1 more source

Cancer cachexia [PDF]

QJM: An International Journal of Medicine, 2005
Cancer cachexia is a severe debilitating disorder for which there are currently few therapeutic options. It is driven by the release of pro-inflammatory cytokines and cachectic factors by both host and tumour. Over the past few years, basic science advances have begun to reveal the breadth and complexity of the immunological mechanisms involved, and in
J N, Gordon, S R, Green, P M, Goggin
openaire   +2 more sources

Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series. [PDF]

Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints.
Hjermstad, MJ, McMillan, D, Bye, A, Arends, J, Sayers, J, Sousa, MS, Leesahatsawat, K, Simpson, MR, Skipworth, RJE, Ottestad, IO, Fallon, M, Balstad, TR, McDonald, J, Cancer Cachexia Endpoints Working Group,, Anker, SD, Brown, LR, Vagnildhaug, OM, Laird, BJA, Solheim, TS, Philips, I, Dolan, RD, Thompson, J, Jakobsen, G, McGovern, J, Roeland, EJ, Dajani, O, Yule, MS   +26 more
core   +3 more sources

Why cachexia kills: examining the causality of poor outcomes in wasting conditions [PDF]

, 2013
Weight loss is the hallmark of any progressive acute or chronic disease state. In its extreme form of significant lean body mass (including skeletal muscle) and fat loss, it is referred to as cachexia.
Anker, SD, Stenvinkel, Peter, Kovesdy, Csaba P, Sim, John J, Kalantar-Zadeh, Kamyar, Anker, Stefan D, Stenvinkel, P,, Rhee, Connie, Rhee, C, Sim, JJ, Kalantar-Zadeh, K, Kovesdy, CP   +11 more
core   +1 more source

Comparative plasma proteomics in muscle atrophy during cancer‐cachexia and disuse: The search for atrokines

Physiological Reports, 2020
Skeletal muscle atrophy is common across a variety of pathologies. Underlying mechanisms of atrophy differ between pathologies, and in many conditions, circulating factors are tied to muscle atrophy.
Seongkyun Lim, Kirsten R. Dunlap, Megan E. Rosa‐Caldwell, Wesley S. Haynie, Lisa T. Jansen, Tyrone A. Washington, Nicholas P. Greene   +6 more
doaj   +1 more source

Mediators and clinical treatment for cancer cachexia: a systematic review

JCSM Rapid Communications, 2021
Background Cachexia, a complex multi‐organ syndrome, shortens survival time of patients, particularly those with cancer. Many studies and clinical trials have been carried out to identify cachexia‐inducing factors and potential treatments for cancer ...
Zhipeng Cao, Andrew M. Scott, Nick J. Hoogenraad, Laura D. Osellame   +3 more
doaj   +1 more source